🔗 Share this article

While the US undertakes historic revisions to its immunization recommendations, one figure has emerged in a surprising turn: Tracy Beth Høeg, an American of Danish descent physician and epidemiologist who initially gained attention by casting doubt on COVID-19 shots throughout the pandemic and has concentrated on potential fatalities following Covid immunization in her recent tenure at the Food and Drug Administration.

Scheduled Overhauls to Childhood Immunization Schedule

Agency leaders planned to unveil major changes to the childhood vaccination calendar earlier this month, aligning the US with Denmark’s vaccine program, it is understood – a major change that would put the US at odds with a large portion of the international standard with no evidence for public health gain. The announcement has been delayed until the next year.

Rather than Vinay Prasad, Høeg is scheduled to address the audience at the meeting. She was just designated interim head of the FDA’s drug evaluation center, the fifth person to head the division this year.

Consolidating Power at the FDA

The acting appointment could signify a closer partnership between the pharmaceutical and vaccine branches as Dr. Høeg and Prasad solidify control at the FDA – and it suggests a renewed priority upon rolling back already-approved vaccines at the FDA.

Høeg has frequently advocated for discontinuing certain pediatric vaccine recommendations in the US so as to align more like Denmark's approach, a country with universal health coverage and a population roughly the size of the state of Wisconsin.

In her initial comments, she has continued to focus on immunizations – traditionally the purview of Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to drug regulation.

Doubts Over Qualifications

The appointee has no apparent experience in pharmaceutical research, oversight or administrative roles, which has been standard for former directors of the biologics center. She has served at the FDA as a top consultant to the agency head and CBER since March.

“She doesn’t seem to have any of the qualifications” for running the CDER, said a neurologist and psychiatrist. “She’s never run a scientific study. She has no expertise in running a sizeable institution. She has no expertise in drug approvals.”

Previous directors of the center would “be deeply familiar with legal statutes and the underlying principles of pharmaceutical innovation”, noted Dr. Janet Woodcock. “Clearly, she lacks the sort of resume that prior appointees who headed the center have had.”

This division has an immense workload at the FDA, the former commissioner pointed out.

“The public just pays attention on the new drug program, but the off-patent medication office clears a multitude of generic medications. There’s a biosimilars program, non-prescription drug unit and other areas, and every single one need to be supervised,” Woodcock said. “The responsibility you overlook, that is precisely what that I always told people is going to cause problems.”

Furthermore, a major management component to the job, which manages in excess of 5,000 employees. “It’s a huge management job, if you do it right,” she said.

Response and Controversial Policies

In response to concerns about Høeg’s fitness for the role and whether this selection indicates greater collaboration among FDA leaders on vaccines, a press secretary said that the “concerns rely on flawed premises”.

“Her resume is consistent with the duties of her position,” the official said, noting the period Dr. Høeg spent advising the FDA commissioner on “pharmaceutical safety and oversight research, including predictive safety algorithms and shot safety tracking”.

As acting director, Høeg inherits the agency head's controversial priority voucher program, a disputed one-day medication authorization process that reportedly worried her preceding directors. “By what process are these medications being picked for this expedited pathway? Who makes the choices?” Howard asked. “There’s a lot of secrecy going on at the FDA right now.”

Overall, he remarked, “the agency appears to be shifting towards laxer regulations of most medications, aside from shots.”

Public History on Vaccines

With immunizations, Høeg has a more established, if troubling, past, critics said. She published a research paper using non-validated volunteer-provided data to estimate the frequency of heart inflammation following Covid vaccination. She advised the Florida chief medical officer Joseph Ladapo, who allegedly have altered data to indicate COVID-19 vaccines are riskier than they are.

Among her “policy goals” for the current federal leadership featured altering guidelines for novel immunizations and discontinuing “unnecessary” vaccines, she remarked after the election on a online show. At the FDA, Høeg has according to sources suggested preventing adolescent males from obtaining Covid vaccines.

“She is an complete dogmatist who starts off with her preconceived notions and reverse-engineers to fit the science in a very disingenuous, untruthful fashion,” Howard said.

Gaining Influence and a “Push for Payback”

Høeg joined fellow dissenters, {like|